je.st
news
KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
2015-04-19 14:30:00| Merck.com - Product News
Dateline City: PHILADELPHIA ...in a Phase 3 Study of Patients with Advanced Melanoma Data from KEYNOTE-006 Study Presented at AACR Annual Meeting and Published in the New England Journal of Medicine Merck Plans to Submit sBLA for First-Line Indication in Advanced Melanoma in Mid-2015 PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the randomized, pivotal Phase 3 study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, KEYTRUDA (pembrolizumab) was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). On March 24, 2015, Merck announced that KEYNOTE-006 would be stopped early based on these data (link). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: free
rate
response
compared
Category:Biotechnology and Pharmaceuticals